Around that time, the breast cancer genes BRCA1 and BRCA2 had just been cloned, through large transnational collaborations led by Mary-Claire King and Michael Stratton, to identify the genetic defect in women with a high risk of developing familial breast and ovarian cancer. This evidence concerns the gene BRCA2 and breast carcinoma.